advertisement
Trials 43
Showing records 1 to 25 | Display only abstracts in Trials from IGR 22-4105903 Factors impacting participation in research during the COVID-19 pandemic: results from a survey of patients in the ophthalmology outpatient department
Abdulhussein D
Trials 2022; 23: 823 (IGR: 23-3)
106213 Treatment of nonarteritic anterior ischemic optic neuropathy with an endothelin antagonist: ENDOTHELION (ENDOTHELin antagonist receptor in Ischemic Optic Neuropathy)-a multicentre randomised controlled trial protocol
Chiquet C
Trials 2022; 23: 916 (IGR: 23-3)
105903 Factors impacting participation in research during the COVID-19 pandemic: results from a survey of patients in the ophthalmology outpatient department
Abdulhussein D
Trials 2022; 23: 823 (IGR: 23-3)
106213 Treatment of nonarteritic anterior ischemic optic neuropathy with an endothelin antagonist: ENDOTHELION (ENDOTHELin antagonist receptor in Ischemic Optic Neuropathy)-a multicentre randomised controlled trial protocol
Vignal C
Trials 2022; 23: 916 (IGR: 23-3)
105903 Factors impacting participation in research during the COVID-19 pandemic: results from a survey of patients in the ophthalmology outpatient department
Yap TE
Trials 2022; 23: 823 (IGR: 23-3)
106213 Treatment of nonarteritic anterior ischemic optic neuropathy with an endothelin antagonist: ENDOTHELION (ENDOTHELin antagonist receptor in Ischemic Optic Neuropathy)-a multicentre randomised controlled trial protocol
Gohier P
Trials 2022; 23: 916 (IGR: 23-3)
105903 Factors impacting participation in research during the COVID-19 pandemic: results from a survey of patients in the ophthalmology outpatient department
Manzar H
Trials 2022; 23: 823 (IGR: 23-3)
106213 Treatment of nonarteritic anterior ischemic optic neuropathy with an endothelin antagonist: ENDOTHELION (ENDOTHELin antagonist receptor in Ischemic Optic Neuropathy)-a multicentre randomised controlled trial protocol
Heron E
Trials 2022; 23: 916 (IGR: 23-3)
105903 Factors impacting participation in research during the COVID-19 pandemic: results from a survey of patients in the ophthalmology outpatient department
Miodragovic S; Cordeiro F
Trials 2022; 23: 823 (IGR: 23-3)
106213 Treatment of nonarteritic anterior ischemic optic neuropathy with an endothelin antagonist: ENDOTHELION (ENDOTHELin antagonist receptor in Ischemic Optic Neuropathy)-a multicentre randomised controlled trial protocol
Thuret G; Rougier MB; Lehmann A; Flet L; Quesada JL; Roustit M; Milea D; Pepin JL;
Trials 2022; 23: 916 (IGR: 23-3)
98455 Guided meditation for vision acuity training on adolescent myopia: study protocol for an open-label, prospective, multicenter, randomized controlled trial
Li Y
Trials 2022; 23: 16 (IGR: 22-4)
98560 Nicotinamide riboside as a neuroprotective therapy for glaucoma: study protocol for a randomized, double-blind, placebo-control trial
Leung CKS; Ren ST
Trials 2022; 23: 45 (IGR: 22-4)
98455 Guided meditation for vision acuity training on adolescent myopia: study protocol for an open-label, prospective, multicenter, randomized controlled trial
Zhu L; Wang R
Trials 2022; 23: 16 (IGR: 22-4)
98560 Nicotinamide riboside as a neuroprotective therapy for glaucoma: study protocol for a randomized, double-blind, placebo-control trial
Chan PPM; Wan KHN; Wan KHN
Trials 2022; 23: 45 (IGR: 22-4)
98455 Guided meditation for vision acuity training on adolescent myopia: study protocol for an open-label, prospective, multicenter, randomized controlled trial
Yang X
Trials 2022; 23: 16 (IGR: 22-4)
98560 Nicotinamide riboside as a neuroprotective therapy for glaucoma: study protocol for a randomized, double-blind, placebo-control trial
Kam AKW
Trials 2022; 23: 45 (IGR: 22-4)
98455 Guided meditation for vision acuity training on adolescent myopia: study protocol for an open-label, prospective, multicenter, randomized controlled trial
Jiang X; Lu T
Trials 2022; 23: 16 (IGR: 22-4)
98560 Nicotinamide riboside as a neuroprotective therapy for glaucoma: study protocol for a randomized, double-blind, placebo-control trial
Lai GWK; Chiu VSM; Ko MWL; Ko MWL; Yiu CKF; Yu MCY
Trials 2022; 23: 45 (IGR: 22-4)
90762 Effect of medically lowering intraocular pressure in glaucoma suspects with high myopia (GSHM study): study protocol for a randomized controlled trial
Lin FB; Da Chen S; Song YH; Wang W; Jin L; Liu BQ; Liu YH; Chen ML; Gao K; Friedman DS; Jonas JB; Aung T; Lv L; Liu YZ; Zhang XL;
Trials 2020; 21: 813 (IGR: 21-3)
72661 Laser peripheral iridotomy versus laser peripheral iridotomy plus laser peripheral iridoplasty in the treatment of multi-mechanism angle closure: study protocol for a randomized controlled trial
Chen S
Trials 2017; 18: 130 (IGR: 18-4)
72660 A prospective, randomised, placebo-controlled, double-masked, three-armed, multicentre phase II/III trial for the Study of a Topical Treatment of Ischaemic Central Retinal Vein Occlusion to Prevent Neovascular Glaucoma - the STRONG study: study protocol f
Lorenz K; Scheller Y
Trials 2017; 18: 128 (IGR: 18-4)
72661 Laser peripheral iridotomy versus laser peripheral iridotomy plus laser peripheral iridoplasty in the treatment of multi-mechanism angle closure: study protocol for a randomized controlled trial
Lv J; Fan S
Trials 2017; 18: 130 (IGR: 18-4)
72660 A prospective, randomised, placebo-controlled, double-masked, three-armed, multicentre phase II/III trial for the Study of a Topical Treatment of Ischaemic Central Retinal Vein Occlusion to Prevent Neovascular Glaucoma - the STRONG study: study protocol f
Bell K; Grus F
Trials 2017; 18: 128 (IGR: 18-4)
72661 Laser peripheral iridotomy versus laser peripheral iridotomy plus laser peripheral iridoplasty in the treatment of multi-mechanism angle closure: study protocol for a randomized controlled trial
Zhang H
Trials 2017; 18: 130 (IGR: 18-4)
72660 A prospective, randomised, placebo-controlled, double-masked, three-armed, multicentre phase II/III trial for the Study of a Topical Treatment of Ischaemic Central Retinal Vein Occlusion to Prevent Neovascular Glaucoma - the STRONG study: study protocol f
Ponto KA
Trials 2017; 18: 128 (IGR: 18-4)
